Family Capital Trust Co decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 39,839 shares of the company’s stock after selling 218 shares during the period. Johnson & Johnson comprises approximately 1.9% of Family Capital Trust Co’s portfolio, making the stock its 12th biggest holding. Family Capital Trust Co’s holdings in Johnson & Johnson were worth $5,931,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Lake Point Wealth Management grew its holdings in Johnson & Johnson by 144.4% in the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares during the last quarter. Islay Capital Management LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $42,000. FAI Wealth Management grew its holdings in Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC boosted its stake in shares of Johnson & Johnson by 909.1% during the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after acquiring an additional 300 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors.
Johnson & Johnson stock opened at $148.10 on Friday. The stock’s 50-day moving average is $148.57 and its 200-day moving average is $146.59. The company has a market cap of $389.92 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
A number of research firms recently commented on JNJ. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the company from $161.00 to $164.00 in a research note on Monday, July 20th. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective on the stock. in a research note on Tuesday, July 7th. Credit Suisse Group increased their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Raymond James increased their target price on Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $164.93.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Find a Trading Strategy That Works
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.